topic report
National Breast Cancer Awareness Month pink ribbon
Favicon Fierce Biotech

After Enhertu: The slow hunt for next-gen HER2 breast cancer drugs

From dual-payload ADCs to bispecifics and radioligands, drugmakers are hunting for answers either after Enhertu progression or to replace it.
Angus Liu Oct 28, 2026 9:00am
Magnifying glass with pills on blue

Regulatory tracker: Ilumya's expansion; Bayer gets 1st FXIa nod

Oct 30, 2026 3:41pm
Future road sign

AbbVie touts robust Q3 as analysts query growth past immunology

Oct 30, 2026 3:15pm
showdown clash versus vs crash lightning fight dispute

The Oral GLP-1 Tracker: Scripts rise for Foundayo, Wegovy pill

Oct 30, 2026 2:40pm
Sanofi headquarters Sanofi

Amid Dupixent boom, Sanofi looks hard at its R&D future

Oct 30, 2026 11:50am
AZ

AstraZeneca launches $1.5B savings plan to fuel pipeline growth

Oct 30, 2026 10:46am
More News

Pfizer's flooded India injectables plant faces long recovery

Oct 30, 2026 10:20am

Enhertu successor, ESMO, Gilead—Fierce Pharma Asia

Oct 30, 2026 8:45am

Lilly lifts guidance on back of another lucrative GLP-1 quarter

Oct 29, 2026 3:31pm

Lenz plans for major layoffs and a CEO switch in Q4

Oct 29, 2026 3:15pm